Research Article

COVID-19 Vaccination Intention and Vaccine Hesitancy among Patients with Autoimmune and Autoinflammatory Rheumatological Diseases: A Survey

Samar Tharwat 1, Haidy Adel Abdelsalam 2, Adel Abdelsalam 1, and Mohammed Kamal Nassar 3

1Rheumatology & Immunology Unit, Department of Internal Medicine, Faculty of Medicine, Mansoura University, Mansoura, Egypt
2Mansoura Manchester Programme for Medical Education, Faculty of Medicine, Mansoura University, Mansoura, Egypt
3Mansoura Nephrology & Dialysis Unit (MNDU), Department of Internal Medicine, Faculty of Medicine, Mansoura University, Mansoura, Egypt

CorrespondenceshouldbeaddressedtoSamarDZ_harwat;samartharwat2000@yahoo.com

Received 23 October 2021; Revised 21 November 2021; Accepted 23 November 2021; Published 31 January 2022

Academic Editor: Ozgur Kasapcopur

Copyright © 2022 Samar Tharwat et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Coronavirus disease 2019 (COVID-19) vaccine hesitancy or refusal has arisen as a major global public health concern. The aim of this study was to address the attitudes of patients with autoimmune and autoinflammatory rheumatological diseases (AIIRDs) about COVID-19 vaccination and investigate the factors that influence their decision. Methods. This interview-based cross-sectional study was carried out on AIIRD patients at the period between 15 August and 15 September 2021. The questionnaire included socioeconomic data, intention to receive COVID-19 vaccine, AIIRD subtype, disease duration, associated comorbidities, history of COVID-19, beliefs and attitudes towards COVID-19, and conventional vaccination in general and COVID-19 vaccine in particular, in addition to COVID-19 vaccination status. Results. A total of 206 AIIRD patients were included, with a mean age of 37.61 years (SD = 10.67), and 84% were females. The percentage of vaccine acceptance was 70.39%, while only 16.02% were hesitant and 13.59% were resistant to COVID-19 vaccination. About one-fourth of patients reported getting infected with COVID-19. Of them, 15.1% were hospitalized and 5.7% were admitted at the intensive care unit (ICU). Most of the AIIRD patients (77.2%) believed that they are at a higher risk of getting COVID-19. The main motivation for vaccine acceptance was the fear of being infected (41.4%). About 40% of vaccine nonacceptants fear about the serious side effects of COVID-19 vaccine. Conclusion. There is a high acceptability rate of COVID-19 vaccination among AIIRD patients. Public health workers and policymakers must emphasize efficient COVID-19 vaccine acceptance messaging for all AIIRD patients.

1. Background

Coronavirus disease 2019, which is known as COVID-19, is caused by a new coronavirus termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. COVID-19 was declared a global pandemic by the World Health Organization (WHO) on March 11, 2020 [2]. The COVID-19 pandemic is now without a doubt not only a global health emergency but also a severe global economic downturn, as the death rate increases and economies are intentionally shut down [3].

Autoimmune and autoinflammatory rheumatological diseases (AIIRDs) are a diverse group of disorders that typically affect the musculoskeletal system and connective tissue [4]. In comparison to the general population, the prevalence of COVID-19 among AIIRD patients was shown to be higher [5, 6]. Preventive lifestyle measures, such as social distancing and the use of personal protective equipment, have been proposed as effective techniques to minimize the rate of SARS-CoV-2 infection in AIIRD patients [7]. In the general population, as well as in individuals with AIIRDs, vaccination is an important and effective tool in
preventing COVID-19. Additionally, people who are vaccinated against this infection are less likely to develop severe disease [8]. Rapid development of safe and efficient COVID-19 vaccinations has the potential to halt the global COVID-19 epidemic.

However, vaccine hesitancy, or the unwillingness or refusal to be vaccinated, has arisen as a major global public health concern, particularly because it may hinder the ability to achieve herd immunity status [9–11].

AIIRD patients are considered a priority group for COVID-19 vaccination [12]. However, little is known about their beliefs and awareness of COVID-19 vaccination. Vaccine hesitancy or resistance in those with AIIRDs can be a roadblock [13].

As a result, it is important to know AIIRD patients’ attitudes towards COVID-19 vaccination. It would be useful to know this in order to design targeted strategies to improve acceptability and overcome the hesitancy problem. To the best of our knowledge, vaccine acceptability among AIIRD patients, as well as actual translation into vaccine uptake, has not yet been assessed in Egypt.

As a result, the aim of this study was to determine the level of intention to get vaccinated against COVID-19 among Egyptian patients with AIIRDs, as well as to estimate their knowledge and beliefs towards COVID-19 vaccination.

2. Methods

2.1. Study Design and Settings. This interview-based cross-sectional study was carried out at the period from 15 August to 15 September at a rheumatology and immunology unit in Lower Egypt. The work complies with the ethical standards of the 1995 Helsinki Declaration and was approved by the institutional review board of Mansoura University (Approval No: R.21.10.1468). The study included consecutive patients with the diagnosis of AIIRDs visiting the outpatient clinic. Patients aged less than 18 years or who had degenerative joint diseases unrelated to AIIRDs and neurological or psychological disabilities were excluded from the start. All participants were provided with detailed information about the study, and informed written consent was obtained from them.

2.2. The Questionnaire. The questionnaire was prepared and then revised and refined. After being translated, it was distributed to the patients in Arabic. A pilot study was conducted to validate the questionnaire, and 5 rheumatology staff members reviewed the correctness of the translation, questionnaire design, content, words, comprehension, and ease of completion. The questions were made in an attempt to be as simple as possible, with the answers limited to yes/no (closed-ended questions) except for the questions about assessment of beliefs about conventional vaccination.

The survey included the following areas: socioeconomic data, intention to receive COVID-19 vaccine, AIIRD subtype, disease duration, associated comorbidities, history of COVID-19 and its sequelae, and therapeutic history.

To characterize the distribution of the characteristics, a descriptive analysis was used. The vaccine acceptant (VA) group included AIIRD patients who answered “Yes, absolutely” or “Yes, probably” to the COVID-19 vaccine intention question; the vaccine hesitant (VH) group included those who answered “No, probably not” or “I do not know” to the COVID-19 vaccine intention question; and the vaccine resistant (VR) group included those who answered “No, certainly not” or “No, probably not” to the COVID-19 vaccine intention question (Figure 1).

The questionnaire also included questions about perception, beliefs, and attitudes towards COVID-19, conventional vaccination in general and COVID-19 vaccine in particular, and source of information about COVID-19 vaccine. The document also explored the perceived motivators of COVID-19 vaccination among the VA group and barriers of COVID-19 vaccine among VH and VR groups.

The final part concerned with COVID-19 vaccination. Participants were asked about their COVID-19 vaccination status before proceeding to the rest of the questions. If the participant had been vaccinated, we asked about the type of vaccine and then we asked about side effects separately, including anaphylaxis, skin rash, fever or chills, widespread muscle or joint pain, fatigue or sleepiness, headache, nausea, vomiting, poor appetite, and chest pain or palpitations.

Patients were contacted (in person), and the questionnaire was explained to them, along with trade name examples of generic pharmaceutical names. Patients with a poor level of education were guided on how to fill out the questionnaire. It was created to take about 5 to 10 minutes to be completed. The responses were recorded and transferred into an excel spreadsheet.

2.3. Statistical Analysis. Quantitative data were reported as means ± standard deviation (SD) for parametric variables or median (min-max) for nonparametric variables, while qualitative data were described as percentages and numbers. The Shapiro–Wilks test was employed to determine the normality of the variable distribution. The one-way ANOVA test was used for normally distributed data, while the Kruskal–Wallis test was used for nonnormally distributed variables when comparing VA, VH, and VR groups. For comparing qualitative variables, the chi-square and Fisher exact tests were used. P value < 0.05 was considered significant.

3. Results

3.1. Demographic Characteristics and Clinical Data. A total of 206 AIIRD patients were included in the study (Table 1), with a mean age of 37.61 years (SD = 10.67), 84% were females, and most of them (88.3%) were educated. The percentage of vaccine acceptance was high (70.39%), while only 16.02% of the participants were hesitant and 13.59% were resistant to COVID-19 vaccination.

As shown in Table 2, the most encountered AIIRDs were systemic lupus erythematosus (SLE) (41.3%), rheumatoid arthritis (RA) (26.2%), systemic sclerosis (SSc) (14.1%), and...
Intention to be vaccinated against COVID-19 (n=206)

- No, certainly not (n=24)
- No, probably not (n=17)
- Does not know (n=20)
- Yes, probably (n=44)
- Yes, absolutely (n=101)
- Nothing will change the intention (n=4)
- Could change the intention (n=13)

Vaccine resistant (n=28)
Vaccine hesitant (n=33)
Vaccine acceptant (n=145)

Figure 1: Classification of AIIRD patients according to the intention to receive COVID-19 vaccine (n=206).

Table 1: Demographic characteristics of the AIIRD population according to their decision regarding the COVID-19 vaccine (n=206).

| Variables, mean ± SD or n (%) | Total (n=206) | COVID-19 vaccine acceptant group (n=145) | COVID-19 vaccine hesitant group (n=33) | COVID-19 vaccine resistant group (n=28) | P |
|--------------------------------|---------------|------------------------------------------|----------------------------------------|----------------------------------------|---|
| Age (years)                   | 37.61 ± 10.67 | 37.45 ± 10.44                            | 38.9 ± 12                              | 36.43 ± 10.4                           | 0.66 |
| Sex                           |               |                                          |                                        |                                        | 0.914 |
| Female                        | 173 (84)      | 122 (84.1)                               | 27 (81.8)                              | 24 (85.7)                              | 0.294 |
| Male                          | 33 (16)       | 23 (15.9)                                | 6 (18.2)                               | 4 (14.3)                               | 0.198 |
| Marital status                |               |                                          |                                        |                                        | 0.877 |
| Single                        | 48 (23.3)     | 30 (20.7)                                | 11 (33.3)                              | 7 (25)                                 | 0.555 |
| Married                       | 158 (76.7)    | 115 (79.3)                               | 22 (66.7)                              | 21 (75)                                | 0.463 |
| Occupation                    |               |                                          |                                        |                                        | 0.616 |
| Employed                      | 56 (27.2)     | 38 (26.2)                                | 11 (33.3)                              | 7 (25)                                 | 0.573 |
| Not employed                  | 134 (65)      | 99 (69.3)                                | 18 (54.5)                              | 17 (60.7)                              | 0.753 |
| Retired                       | 3 (1.5)       | 3 (2.1)                                  | 0                                      | 0                                      | 0.823 |
| Not able to work due to disability | 9 (4.4) | 4 (2.8)                                  | 3 (9.1)                                | 2 (7.1)                                | 0.677 |
| Student                       | 4 (1.9)       | 1 (0.7)                                  | 1 (3)                                  | 2 (7.1)                                | 0.555 |
| Residence                     |               |                                          |                                        |                                        | 0.463 |
| Rural                         | 89 (43.2)     | 61 (42.1)                                | 15 (45.5)                              | 13 (46.4)                              | 0.573 |
| Urban                         | 117 (56.8)    | 84 (57.9)                                | 18 (54.5)                              | 15 (53.6)                              | 0.573 |
| Education                     |               |                                          |                                        |                                        | 0.463 |
| None                          | 22 (10.7)     | 15 (10.3)                                | 4 (12.1)                               | 3 (10.7)                               | 0.616 |
| Middle School                 | 31 (15)       | 21 (14.5)                                | 5 (15.2)                               | 5 (17.9)                               | 0.573 |
| High School                   | 73 (35.4)     | 58 (40)                                  | 9 (27.3)                               | 6 (21.4)                               | 0.573 |
| College degree                | 63 (30.6)     | 41 (28.3)                                | 13 (39.4)                              | 9 (32.1)                               | 0.573 |
| Postgraduate                  | 17 (8.3)      | 10 (6.9)                                 | 2 (6.1)                                | 5 (17.9)                               | 0.573 |
| Active lifestyle              | 89 (43.2)     | 66 (45.5)                                | 12 (36.4)                              | 11 (39.3)                              | 0.573 |
| Smoking habit                 |               |                                          |                                        |                                        | 0.463 |
| Nonsmoker                     | 187 (90.8)    | 131 (90.3)                               | 29 (87.9)                              | 27 (96.4)                              | 0.463 |
| Former smoker                 | 8 (3.9)       | 6 (4.1)                                  | 1 (3)                                  | 1 (3.6)                                | 0.463 |
| Current smoker                | 11 (5.3)      | 8 (5.5)                                  | 3 (9.1)                                | 0                                      | 0.463 |
| Family income                 |               |                                          |                                        |                                        | 0.463 |
| Not enough                    | 34 (16.5)     | 17 (11.7)                                | 10 (30.3)                              | 7 (25)                                 | 0.463 |
| Enough but no saving          | 124 (60.2)    | 97 (66.9)                                | 14 (42.4)                              | 13 (46.4)                              | 0.463 |
| Enough and saving             | 48 (23.3)     | 31 (21.4)                                | 9 (27.3)                               | 8 (28.6)                               | 0.463 |

*p < 0.05.
Behçet’s disease (BD) (10.7%). The median (min-max) disease duration of AIIRD was 5 (0.5–35) years. About one-fourth of patients with AIIRDs reported that they had suspected or confirmed COVID-19 in the previous 12 months. Of them, 15.1% were hospitalized and 5.7% were admitted at the intensive care unit (ICU).

### 3.2. Perception, Beliefs, and Attitudes and Sources of Information

As illustrated in Table 3, most of the AIIRD patients (77.2%) believed that they are at a higher risk of getting COVID-19 infection due to AIIRD. Even though, most of them thought that they are more susceptible to severe COVID-19 and COVID-19 vaccine adverse events due to AIIRD (83.5% and 75.2%, respectively). Confidence in the efficacy, security, usefulness, and estimated knowledge of conventional vaccines (excluding COVID-19 vaccines) was 7/10, 7/10, 7/10, and 6/10, respectively. Of the patients who accepted the vaccine, 89.7% were confident of its importance and 90% considered it essential for everyone in the community. However, only 30% of those who were vaccine resistant admitted its importance.

### Table 2: Clinical and therapeutic data of the AIIRD population according to their decision regarding the COVID-19 vaccine (n = 206).

| Variables, median (min-max) or n (%) | Total (n = 206) | COVID-19 vaccine acceptant group (n = 145) | COVID-19 vaccine hesitant group (n = 33) | COVID-19 vaccine resistant group (n = 28) | P
|-------------------------------------|----------------|--------------------------------------------|------------------------------------------|------------------------------------------|-------|
| **AIIRD subtype**                   |                |                                            |                                          |                                          | 0.749 |
| SLE                                | 85 (41.3)      | 61 (42.1)                                 | 12 (36.4)                                | 12 (42.9)                                |       |
| RA                                 | 54 (26.2)      | 38 (26.2)                                 | 7 (21.2)                                 | 9 (32.1)                                 |       |
| SSC                                | 29 (14.1)      | 20 (13.8)                                 | 4 (12.1)                                 | 5 (17.9)                                 |       |
| BD                                 | 22 (10.7)      | 18 (12.4)                                 | 4 (12.1)                                 | 0                                        |       |
| Primary APLs                        | 3 (1.5)        | 2 (1.4)                                   | 1 (3)                                    | 0                                        |       |
| AS                                 | 3 (1.5)        | 1 (0.7)                                   | 1 (3)                                    | 3 (1.6)                                  |       |
| DM                                 | 2 (1)          | 1 (0.7)                                   | 0                                        | 1 (3.6)                                  |       |
| PsA                                | 1 (0.5)        | 1 (0.7)                                   | 0                                        | 0                                        |       |
| Vasculitis                          | 1 (0.5)        | 1 (0.7)                                   | 0                                        | 0                                        |       |
| AOSD                               | 1 (0.5)        | 1 (0.7)                                   | 0                                        | 0                                        |       |
| Overlap syndrome (SLE, RA)          | 5 (2.4)        | 1 (0.7)                                   | 4 (12.1)                                 | 0                                        |       |
| **Disease duration (years)**        | 5 (0.5–35)     | 5 (0.5–28)                                | 5 (0.5–35)                               | 8 (0.5–19)                               | 0.477 |
| **Self-rated overall disease activity** | 6 (0–10)     | 6 (0–10)                                 | 6 (0–10)                                 | 5 (0–10)                                 | 0.381 |
| **Associated comorbidities**        |                |                                            |                                          |                                          |       |
| Diabetes mellitus                   | 19 (9.2)       | 13 (9)                                    | 5 (15.2)                                 | 1 (3.6)                                  | 0.293 |
| Hypertension                        | 45 (21.8)      | 30 (20.7)                                 | 11 (33.3)                                | 4 (14.3)                                 | 0.167 |
| Chronic lung disease                | 18 (8.7)       | 13 (9)                                    | 3 (9.1)                                  | 2 (3.1)                                  | 0.95  |
| Ischemic heart disease              | 2 (1)          | 2 (1.4)                                   | 0                                        | 0                                        | 0.655 |
| Others                              | 56 (27.2)      | 39 (26.9)                                 | 11 (33.3)                                | 6 (21.4)                                 | 0.577 |
| **History of COVID-19**             | 53 (25.7)      | 42 (29)                                   | 3 (9.1)                                  | 8 (28.6)                                 | 0.057 |
| Hospitalization                     | 8 (15.1)       | 6 (14.3)                                  | 1 (33.3)                                 | 1 (12.5)                                 | 0.629 |
| ICU admission                       | 3 (5.7)        | 2 (4.8)                                   | 1 (33.3)                                 | 0                                        | 0.079 |
| **COVID-19 among relatives or friends** | 84 (40.8)   | 55 (37.9)                                 | 16 (48.5)                                | 13 (46.4)                                | 0.478 |
| Hospitalization                     | 40 (19.4)      | 22 (15.2)                                 | 10 (30.3)                                | 8 (28.6)                                 | 0.067 |
| Death                               | 23 (11.2)      | 14 (9.7)                                  | 6 (18.2)                                 | 3 (10.7)                                 | 0.389 |
| **Therapeutic data**                |                |                                            |                                          |                                          |       |
| Corticosteroids                     | 138 (67)       | 101 (69.7)                                | 20 (60.6)                                | 17 (60.7)                                | 0.457 |
| Hydroxychloroquine                  | 94 (45.6)      | 64 (44.1)                                 | 19 (57.6)                                | 11 (39.3)                                | 0.291 |
| Leflunomide                         | 22 (10.7)      | 17 (11.7)                                 | 2 (6.1)                                  | 3 (10.7)                                 | 0.638 |
| Methotrexate                        | 66 (32)        | 50 (34.5)                                 | 7 (21.2)                                 | 9 (32.1)                                 | 0.339 |
| Mycophenolate mofetil               | 42 (20.4)      | 29 (20)                                   | 7 (21.2)                                 | 6 (21.4)                                 | 0.977 |
| Adalimumab                          | 4 (1.9)        | 3 (2.1)                                   | 1 (3)                                    | 0                                        | 0.681 |
| Infliximab                          | 4 (1.9)        | 1 (0.7)                                   | 2 (6.1)                                  | 1 (3.6)                                  | 0.105 |
| Etanercept                          | 4 (1.9)        | 2 (1.4)                                   | 2 (6.1)                                  | 0                                        | 0.156 |
| Golimumab                           | 1 (0.5)        | 1 (0.7)                                   | 0                                        | 0                                        | 0.810 |
| Tocilizumab                         | 1 (0.5)        | 1 (0.7)                                   | 0                                        | 0                                        | 0.810 |
| Secukinumab                         | 1 (0.5)        | 1 (0.7)                                   | 0                                        | 0                                        | 0.810 |
| Rituximab                           | 2 (1)          | 1 (3)                                     | 1 (3.6)                                  | 0                                        | 0.09  |
| Adherence to therapy                | 175 (85)       | 126 (86.9)                                | 26 (78.8)                                | 23 (82.1)                                | 0.388 |

AOSD: adult-onset Still’s disease, APLs: antiphospholipid syndrome, AS: ankylosing spondylitis, BD: Behcet’s disease, DM: dermatomyositis, PsA: psoriatic arthritis, RA: rheumatoid arthritis, SLE: systemic lupus erythematosus, SSc: systemic sclerosis.
Concerning the sources of information about COVID-19 vaccine, television (TV) represented the major one for AIIRD patients from rural areas (70%), while the Internet attained the highest percentage (nearly 50%) in urban areas. Rheumatologists were the source of knowledge in 30% in AIIRD patients from urban areas and 12% in those from rural areas. General practitioners rated the least one with the same ratio in both regions as presented in Figure 2.

3.3. The Perceived Motivators and Barriers of COVID-19 Vaccination. As illustrated in Figure 3, the main motivations for vaccine acceptance were the fear of being infected (41.4%), the perception of high risk of COVID-19 (38.6%), and the wish to return to normal life as soon as possible (29%).

Figure 4 demonstrates the barriers to COVID-19 vaccination acceptability in VH and VA groups. About 40% fear about the serious side effects of COVID-19 vaccine. Approximately one-third (34%) preferred to wait until they have more experience about these new vaccines, while 28% were afraid of mild side effects and 26% doubted the efficacy of the COVID-19 vaccines.

3.4. List of Types and Adverse Effects of Received COVID-19 Vaccines. Among the studied 206 AIIRD population,
Figure 2: Sources of information about COVID-19 vaccine among the AIIRD population according to the residence (rural versus urban) ($n = 206$).

Figure 3: The motivators of COVID-19 vaccination among the COVID-19 vaccine acceptant group ($n = 145$).

Figure 4: Barriers of COVID-19 vaccination among the COVID-19 vaccine hesitant and resistant groups ($n = 61$).
37(17.96%) patients have received COVID-19 vaccine. Sinopharm and AstraZeneca were the most common used vaccines (29.7% and 24.3%, respectively). The most common postvaccination symptoms were widespread muscle and/or joint pain (40.5%) and fever or chills (32.4%), followed by fatigue and sleepiness (16.2%). The less likely appeared symptoms were mouth dryness (2.7%) and diarrhea (2.7%). Two AIIRD patients reported flare of the existing AIIRD within few days after COVID-19 vaccination (Table 4).

4. Discussion

Nowadays, there is a respectable campaign all over the world to battle against the novel COVID-19 pandemic [14, 15]. As known, vaccination is the most efficient way to eradicate infection [16]. COVID-19 vaccine received different attitudes regarding its acceptance [17]. AIIRD patients have concerns about COVID-19 vaccination [18].

To the best of our knowledge, our study is the first one to determine the attitudes and beliefs towards COVID-19 vaccination among Egyptian patients with AIIRDs. The sample group was divided between vaccine acceptancy, hesitancy, and resistance. This finding illustrates the topic’s dilemma in AIIRD patients, where half of them were willing to get the vaccine. Holding positive beliefs about conventional vaccination in general and COVID-19 vaccine in particular is the most important association of vaccination. The most common sources of information in rural and urban areas were TV and the Internet, respectively, while rheumatologists were the source of knowledge in only 22% of AIIRD patients. The fear of being infected was the main motivation of COVID-19 vaccination acceptance, while fear about serious side effects of the vaccine was the most hindering factor against vaccination.

AIIRD patients have an increased burden of infections due to underlying autoimmune disease [19], comorbidities, and immunosuppressive therapy [20]. Meanwhile, patients with AIIRDs do not appear to be at an elevated risk of SARS-CoV-2 infection in comparison to the general population [21]. Also, pediatric patients with AIIRDs and those receiving biologics may not be at increased risk of neither COVID-19 nor its serious complications [22, 23].

In this study, about one-fourth of patients with AIIRDs reported that they had a history of suspected or confirmed COVID-19 in the previous 12 months. Of them, 15.1% were hospitalized and 5.7% admitted at the intensive care unit (ICU). In AIIRD patients, the overall risk of hospitalization and death related to COVID-19 was not or just marginally elevated [6, 24, 25]. It is, however, critical to maintain optimum AIIRD care and take preventive measures such as vaccination to limit the risk and severity of COVID-19 [26]. The prevalence of severe COVID-19 in patients with AIIRDs is still unclear [27]. Pablos et al. stated that AIIRD patients are susceptible to more severe COVID-19 that necessities hospitalizations [28]. Certain immunomodulatory medications have been suggested to have a possible preventative or therapeutic effect in these patients [29].

Understanding the risk of COVID-19 in AIIRD patients is crucial, and there is still a number of unanswered questions.

| Variables | Vaccinated AIIRD patients (n = 37), n (%) |
|-----------|-----------------------------------------|
| Type of COVID-19 vaccine received |                                      |
| Sinopharm | 11 (29.7)                               |
| AstraZeneca | 9 (24.3)                              |
| Pfizer | 8 (21.6)                                 |
| Sinovac | 4 (10.8)                                 |
| Moderna | 1 (2.7)                                  |
| Others | 4 (10.8)                                 |
| Adverse effects of COVID-19 vaccines |  |
| Widespread muscle/joint pain | 15 (40.5)                             |
| Fever or chills | 12 (32.4)                             |
| Fatigue or sleepiness | 6 (16.2)                              |
| Headache | 6 (16.2)                                 |
| Nausea | 2 (5.4)                                  |
| Vomiting | 2 (5.4)                                 |
| Chest pain-palpitations | 2 (5.4)                               |
| Flare of the existing rheumatic disease | 2 (5.4)                              |
| Rash | 1 (2.7)                                  |
| Poor appetite | 1 (2.7)                               |
| Diarrhea | 1 (2.7)                                |
| Mouth dryness | 1 (2.7)                               |
| New rheumatic or other autoimmune disease | 0                                   |
| Anaphylaxis | 0                                      |

Table 4: List of types and adverse effects of COVID-19 vaccines in AIIRD patients who have received COVID-19 vaccine (n = 37).

It is unknown how SARS-CoV-2 reinfection affects AIIRD patients.

Our study shows that, in August and September 2021, more than half of the AIIRD patients were VA, 16% were VH, and 14% were VR. A similar pattern of results was obtained in another study from Rome where acceptability in AIIRD patients was 54.9% [17]. Also, this is consistent with what has been found in a previous study carried out on 1266 patients with AIIRDs and found that 686 (54.2%) were willing to get vaccinated against COVID-19 and 408 (32.2%) were uncertain, while 172 (13.6%) were unwilling to get vaccinated [8]. In this context, we emphasize the necessity of increasing patient education towards COVID-19 vaccination.

Additionally, few studies found that males were more willing to get vaccinated than females [8, 30, 31]. However, no such difference was found in our study. This finding may be as a result of the female predominance of our study which is probably due to epidemiological facts of AIIRDs. Also, willingness to get COVID-19 vaccine was not associated with comorbidities or immunosuppressive drugs in our cohort.

During the last few years, evidence about the safety, immunogenicity, and efficacy of vaccination in AIIRD patients has markedly grown [20]. The concept of vaccination is refused by nonnegligible numbers of the population [32]. Barello S. et al. suggested that one of the factors of uncertainty is the lack of sense of responsibility towards society and losing the role of becoming an active arm in the eradication of the pandemic [33]. It is uncertain how AIIRDs and immunosuppressive medications will affect AIIRD.
patients’ immunological response to the COVID-19 vaccine because AIIRD patients were not routinely included in vaccination trials. As a result, uncertainties about the efficacy and safety of COVID-19 vaccinations in AIIRD patients may cause clinicians and patients to be hesitant to administer COVID-19 vaccine [34, 35]. However, in a recently published study, COVID-19 vaccine in patients with AIIRD was found to have reduced but acceptable short-term immunogenicity [36]. Also, COVID-19 vaccination resulted in an adequate immunogenic response with a tolerable safety profile in the majority of patients with AIIRDS, according to another study conducted on 686 AIIRD patients and 121 controls [37].

Healthcare providers including rheumatologists need to customize their messages strategically based on the intent to get vaccinated; in low-intention groups, emphasizing the vaccination’s safety may be more effective, whereas in high-accessibility and high-intention groups, emphasizing practical issues such as vaccine cost and logistics may be more beneficial [38].

In this study, about 80% of vaccine nonacceptant patients have the misconception that they are at a risk of developing more adverse effects of the vaccine. Boekel et al. stated that COVID-19 vaccines are well tolerated by patients with autoimmune diseases [31].

Almost all rheumatologists recommend the COVID-19 vaccine for their AIIRD patients even without lowering immunomodulatory drugs [39]. Strong agreement was reached on the consensus that COVID-19 vaccination should not be delayed for patients using hydroxychloroquine, sulfasalazine, leflunomide, apremilast, or IV immunoglobulin. For the majority of the remaining immunomodulatory treatments evaluated, a similar recommendation was reached with moderate consensus [40].

So, rheumatologists can positively influence vaccine acceptance in AIIRD patients through counselling about vaccine efficacy and safety concerns [40]. When vaccination against COVID-19 was advised by a physician, the willingness to get vaccinated increased, and the specialist physician was the most trusted healthcare provider [8].

From the results, it is clear that vaccine acceptancy is strongly associated with positive beliefs and attitudes towards vaccination in general and COVID-19 vaccination in particular. This is in agreement with the VAccinations against COVID-19 (VAXICOV) study [8]. Vaccine uptake has been linked to a lack of vaccine information and poor attitudes regarding vaccination in general [41]. To overcome COVID-19 vaccination skepticism and, hopefully, put a stop to the epidemic, rheumatologists and AIIRD patients urgently require coordinated national and worldwide local awareness campaigns [12].

Our results cast a new light on the sources of information about COVID-19 vaccine in AIIRD patients. In this study, while TV and the Internet were the main sources of information, rheumatologists were considered the source of COVID-19 vaccine information in only one-fifth of AIIRD patients. It is notable that concerns have been raised about patient misinformation about the COVID-19 pandemic and vaccination safety [42]. So, rheumatologists should play a pivotal role in implementing vaccination education programmes [40].

Our results demonstrated that the main motivations for vaccine acceptance were the fear of being infected (41.4%) and the perception of high risk of COVID-19 (38.6%). A similar conclusion was reached by the VAXICOV study in which patients with AIIRDS expressed their willingness to get vaccinated against COVID-19 in order to protect themselves, their families, and the general population [8].

From the results, it is clear that the fear about the serious side effects of COVID-19 vaccine and the doubts about vaccination efficacy are the main barriers to COVID-19 vaccination acceptability, similar to those observed in prior studies [12, 13, 17, 30].

In those who received COVID-19 vaccine, only 2 patients experienced flare of their autoimmune disease few days shortly after COVID-19 vaccination. In a study carried out on 264 patients with AIIRDS who were assessed 4–6 weeks after receiving the second dose of COVID-19 vaccine, only minor side effects were reported and no apparent impact on AIIRD activity was noted [43]. So, further studies are warranted to declare this point.

This study was not without its limitations. The main limitation of this study is the absence of data about non-respondents. The relatively small number of the participants from a single rheumatology center and the lack of data about healthy individuals may be another limitation. Furthermore, the cross-sectional study reflects AIIRD patients’ acceptance and opinions about COVID-19 vaccination during the pandemic. However, people’s attitudes and beliefs may change with time. Finally, our study looked at COVID-19 vaccination acceptance rates under the assumption that the vaccine was free; acceptability might be lower if the vaccine would come with out-of-pocket costs.

However, this study had several strengths; the questionnaire is reliable and straightforward. A face-to-face interview was conducted. The study also examined a wide range of demographic factors and health beliefs about COVID-19 vaccine. The study targeted an Egyptian cohort. To the best of our knowledge, this is the first paper that addresses the intention in Egyptian AIIRD patients towards COVID-19 vaccination.

Further studies on a large number of patients and from different rheumatology centers in Egypt are warranted to confirm these data and help improve the acceptancy of AIIRD patients towards COVID-19 vaccination. Multi-national studies also are also needed to shed light on this topic.

In conclusion, the findings of this study are critical in determining the level of acceptancy and concerns about COVID-19 vaccination among AIIRD patients, as well as identifying motivators and barriers towards COVID-19 vaccination and, hence, recognizing effective strategies for increasing vaccine coverage in those populations including ongoing training and education. Contextual factors, such as media coverage of COVID-19, may influence vaccine beliefs and attitudes.
References

[1] S. Shamim, M. Khan, Z. J. Kharaba, M. Ijaz, and G. Murtaza, “Potential strategies for combating COVID-19,” Archives of Virology, vol. 165, no. 11, pp. 2419–2438, 2020.

[2] B. McKay, J. Calfas, and T. J. T. W. S. I. Ansari, Coronavirus Declared Pandemic by World Health Organization, World Health Organization, Geneva, Switzerland, 2020.

[3] W. van der Wielen and S. Barrios, “Economic sentiment during the COVID pandemic: evidence from search behaviour in the EU,” Journal of Economics and Business, vol. 115, Article ID 105970, 2021.

[4] M. J. Kim, E. B. Lee, Y. W. Song, and J. K. Park, “Profile of common inflammatory markers in treatment-naive patients with systemic rheumatic diseases,” Clinical Rheumatology, vol. 39, no. 10, pp. 2899–2906, 2020.

[5] K. L. Hyrich and P. M. Machado, “Rheumatic disease and COVID-19: epidemiology and outcomes,” Nature Reviews Rheumatology, vol. 17, no. 2, pp. 71–72, 2021.

[6] S. Akiyama, S. Hamdeh, D. Micic, and A. Sakuraba, “Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis,” Annals of the Rheumatic Diseases, vol. 80, no. 3, pp. 384–391, 2021.

[7] A. Pan, L. Liu, C. Wang et al., “Association of public health interventions with the epidemiology of the COVID-19 outbreak in Wuhan, China,” The Journal of the American Medical Association, vol. 323, no. 19, pp. 1915–1923, 2020.

[8] R. Felten, M. Dubois, M. F. Ugarte-Gil et al., “Vaccination against COVID-19: expectations and concerns of patients with autoimmune and rheumatic diseases,” The Lancet Rheumatology, vol. 3, no. 4, pp. e243–e245, 2021.

[9] S. B. Omer, D. A. Salmon, W. A. Orenstein, M. P. Dehart, and N. Halsey, “Vaccine refusal, mandatory immunization, and the risks of vaccine-preventable diseases,” New England Journal of Medicine, vol. 360, no. 19, pp. 1981–1988, 2009.

[10] R. J. Akbar, Ten Threats to Global Health in 2019, World Health Organization, Geneva, Switzerland, 2019.

[11] World Health Organization, Coronavirus Disease (COVID-19): Herd Immunity, Lockdowns and COVID-19 World Health Organization, Geneva, Switzerland, 2021.

[12] C. Campochiaro, G. Trignani, A. Tomelleri, S. Casciniu, and L. Dagna, “Potential acceptance of COVID-19 vaccine in rheumatological patients: a monocentric comparative survey,” Annals of the Rheumatic Diseases, vol. 80, no. 6, pp. 816–817, 2021.

[13] P. Gaur, H. Agrawat, and A. Shukla, “COVID-19 vaccine hesitancy in patients with systemic autoimmune rheumatic disease: an interview-based survey,” Rheumatology International, vol. 41, no. 9, pp. 1601–1605, 2021.

[14] L. S. F. Frederiksen, Y. Zhang, C. Foged, and A. Thakur, “The long road toward COVID-19 herd immunity: vaccine platform technologies and mass immunization strategies,” Frontiers in Immunology, vol. 11, Article ID 1817, 2020.

[15] D. Romer and K. H. Jamieson, “Conspiracy theories as barriers to controlling the spread of COVID-19 in the U.S,” Social Science & Medicine, vol. 263, Article ID 113356, 2020.

[16] N. E. MacDonald, “Vaccine hesitancy: definition, scope and determinants,” Vaccine, vol. 33, no. 34, pp. 4161–4164, 2020.

[17] R. Priori, G. Pellegrino, S. Colafrancesco et al., “SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists,” Annals of the Rheumatic Diseases, vol. 80, no. 7, pp. 953-954, 2021.

[18] M. Sallam, “COVID-19 vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance rates,” Vaccines, vol. 9, no. 2, p. 160, 2021.

[19] K. Au, G. Reed, J. R. Curtis et al., “High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 70, no. 5, pp. 785–791, 2011.

[20] G. Galicia-Hernández, F. Parra-Salcido, P. Ugarte-Martínez, I. Contreras-Yáñez, A. Ponce-de-León, and V. J. C. Pascual-Ramos, “Sustained moderate-to-high disease activity and higher Charlson score are predictors of incidental serious
infection events in RA patients treated with conventional disease-modifying anti-rheumatic drugs: a cohort study in the treat-to-target era,” *Clinical & Experimental Rheumatology*, vol. 34, no. 2, pp. 261–269, 2016.

[21] G. Emmi, A. Bettiol, I. Mattioli et al., “SARS-CoV-2 infection among patients with systemic autoimmune diseases,” *Autoimmunity Reviews*, vol. 19, no. 7, Article ID 102575, 2020.

[22] M. Yildiz, F. Haslak, A. Adrovic, S. Sahin, K. Barut, and O. Kasapcoglu, “The frequency and clinical course of COVID-19 infection in children with juvenile idiopathic arthritis,” *Clinical & Experimental Rheumatology*, vol. 38, pp. 1271–1272, 2020.

[23] F. Haslak, M. Yildiz, A. Adrovic et al., “Management of childhood-onset autoinflammatory diseases during the COVID-19 pandemic,” *Rheumatology International*, vol. 40, no. 9, pp. 1423–1431, 2020.

[24] P. Sarzi-Puttini, D. Marotto, R. Caporali et al., “Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: a multicentre retrospective study,” *Journal of Autoimmunity*, vol. 116, Article ID 102545, 2021.

[25] R. Cordtz, J. Lindhardsen, B. G. Soussi et al., “Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark,” *Rheumatology (Oxford)*, vol. 60, 2020.

[26] D. Zucchi, C. Tani, E. Elefante et al., “Impact of first wave of SARS-CoV-2 infection in patients with systemic lupus erythematosus: weighting the risk of infection and flare,” *PLoS One*, vol. 16, no. 1, Article ID e0245274, 2021.

[27] J. L. Pablos, L. Abasolo, J. M. Álvaro-Gracia et al., “Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases,” *Annals of the Rheumatic Diseases*, vol. 79, no. 9, pp. 1170–1173, 2020.

[28] J. L. Pablos, M. Galindo, L. Carmona et al., “Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study,” *Annals of the Rheumatic Diseases*, vol. 79, no. 12, pp. 1544–1549, 2020.

[29] P. Luo, Y. Liu, L. Qiu, X. Liu, D. Liu, and J. Li, “Tocilizumab treatment in COVID-19: a single center experience,” *Journal of Medical Virology*, vol. 92, no. 7, pp. 814–818, 2020.

[30] L. Boekel, F. Hooijberg, Z. L. E. van Kempen et al., “Perspective of patients with autoimmune diseases on COVID-19 vaccination,” *The Lancet Rheumatology*, vol. 3, no. 4, pp. e241–e243, 2021.

[31] B. Yurttas, B. C. Poyraz, N. Sut et al., “Williness to get the COVID-19 vaccine among patients with rheumatic diseases, healthcare workers and general population in Turkey: a web-based survey,” *Rheumatology International*, vol. 41, no. 6, pp. 1105–1114, 2021.

[32] E. Dubé, C. Laberge, M. Guay, P. Bramadat, R. Roy, and J. Bettinger, “Vaccine hesitancy: an overview,” *Human Vaccines & Immunotherapeutics*, vol. 9, no. 8, pp. 1763–1773, 2013.

[33] S. Barello, T. Nania, F. Dellafiore, G. Graffigna, and R. Caruso, “Vaccine hesitancy” among university students in Italy during the COVID-19 pandemic,” *European Journal of Epidemiology*, vol. 35, no. 8, pp. 781–783, 2020.

[34] L. Rosenbaum, “Escaping catch-22—overcoming COVID vaccine hesitancy,” *The New England Journal of Medicine*, vol. 384, no. 14, pp. 1367–1371, 2021.

[35] M. Schwarzinger, V. Watson, P. Arwidon, F. Alla, and S. Luchini, “COVID-19 vaccine hesitancy in a representative working-age population in France: a survey experiment based on vaccine characteristics,” *The Lancet Public Health*, vol. 6, no. 4, pp. e210–e221, 2021.

[36] A. C. Medeiros-Ribeiro, N. E. Aikawa, C. G. S. Saad et al., “Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial,” *Nature Medicine*, vol. 27, no. 10, pp. 1744–1751, 2021.

[37] V. Furer, T. Evitar, D. Zisman et al., “Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study,” *Annals of the Rheumatic Diseases*, vol. 80, no. 10, pp. 1330–1338, 2021.

[38] H. Chu and S. Liu, “Light at the end of the tunnel: influence of vaccine availability and vaccination intention on people’s consideration of the COVID-19 vaccine,” *Social Science & Medicine*, vol. 286, Article ID 114315, 2021.

[39] R. Hasseli, A. Pfeil, A. Krause et al., “A survey to evaluate knowledge, perceptions and attitudes toward COVID-19 vaccinations among rheumatologists in Germany,” *Rheumatology International*, vol. 41, no. 11, pp. 1949–1956, 2021.

[40] J. R. Curtis, S. R. Johnson, D. D. Anthony et al., “American college of rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 3,” *Arthritis & Rheumatology*, vol. 73, no. 10, pp. e60–e75, 2021.

[41] P. Loubet, S. Kernéis, M. Groh et al., “Attitude, knowledge and factors associated with influenza and pneumococcal vaccine uptake in a large cohort of patients with secondary immune deficiency,” *Vaccine*, vol. 33, no. 31, pp. 3703–3708, 2015.

[42] L. Rajagopala, M. Ford, M. Jasim et al., “OP0009-PARE successful patient education on COVID-19 vaccine safety in a large rheumatology cohort using interactive mobile-phone video technology: context, results, and next steps,” *Annals of the Rheumatic Diseases*, vol. 80, no. 1, 2021.

[43] Y. Braun-Moscovici, M. Kaplan, M. Braun et al., “Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2,” *Annals of the Rheumatic Diseases*, vol. 80, no. 10, pp. 1317–1321, 2021.